reports
Oak Valley Community Bank Welcomes Carlos Chavez as Vice President, Br...
Oak Valley Community Bank Welcomes Carlos Chavez as Vice President, Branch Manager of Stockton Branch OAKDALE, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Oak Valley Community Bank, a wholly owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), is pleased to welcome Carlos Chavez as Vice President, Branch Manager. Chavez will oversee the bank’s Stockton Branch at 2935 West March Lane, where he will be responsible for guiding branch operations, strengthening client relationships, and driving growth through a continued commitment to service excellence. His role will also include supporting t...
Oak Valley Community Bank Announces Leadership Team Promotions
Oak Valley Community Bank Announces Leadership Team Promotions OAKDALE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oak Valley Bancorp (NASDAQ: OVLY), the bank holding company for Oak Valley Community Bank and its Eastern Sierra Community Bank division, today announced the promotions of Bill Nunes to Executive Vice President, Chief Marketing Officer, and Jose Sabala to Senior Vice President, Community Reinvestment Act (CRA) Officer. Bill Nunes — Executive Vice President, Chief Marketing OfficerNunes joined the Bank in 2005 and most recently served as Senior Vice President, Marketing Manage...
Texas Capital Bancshares, Inc. Announces Date for Full Year and Q4 202...
Texas Capital Bancshares, Inc. Announces Date for Full Year and Q4 2025 Operating Results DALLAS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the full year and fourth quarter of 2025 before market on Thursday, January 22, 2026. Executive management will host a conference call and webcast to discuss full year and fourth quarter 2025 operating results on Thursday, January 22, 2026, at 9:00 a.m. EDT. Participants may pre-register for the call by visit...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 L...
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies CORAL GABLES, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced its inclusion in Forbes' esteemed list of America's Most Successful Small-Cap Companies for the year 2026. Catalyst has ranked an impressive 11 out ...
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugur...
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS) Students from The University of Notre Dame Selected to Participate in a Week-long Biopharmaceutical Learning Intensive CORAL GABLES, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The University of Notre Dame and Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced the...
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healt...
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA. 44th Annual J.P. Morgan Healthcare Conference Format: Presentation and one-on-one investor meetings Date: January 15, 2026 Pres...
NBT Bancorp Inc. Announces Date of Fourth Quarter Conference Call
NBT Bancorp Inc. Announces Date of Fourth Quarter Conference Call NORWICH, N.Y., Jan. 02, 2026 (GLOBE NEWSWIRE) -- NBT Bancorp Inc. (“NBT” or the “Company”) (NASDAQ: NBTB) will release details of its financial results for the fourth quarter 2025 on Monday, January 26, 2026, following the market close. The Company will host a conference call at 10:00 a.m. (Eastern) Tuesday, January 27, 2026, to review these results. The audio webcast link, along with the corresponding presentation slides, will be available on the Company’s Event Calendar page at prior to the beginning of the conference c...
CVB Financial Corp. and Heritage Commerce Corp Announce Agreement to M...
CVB Financial Corp. and Heritage Commerce Corp Announce Agreement to Merge Complementary strategic combination to expand Citizens Business Bank’s presence in the Bay Area and to enhance industry-leading financial performance ONTARIO, Calif. and SAN JOSE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- CVB Financial Corp. (Nasdaq: CVBF; together with Citizens Business Bank, National Association, “Citizens”) and Heritage Commerce Corp (Nasdaq: HTBK; together with Heritage Bank of Commerce, “Heritage”), today jointly announced that they have entered into a definitive merger agreement. Under the ...
Catalyst Pharmaceuticals Inc: 1 director
A director at Catalyst Pharmaceuticals Inc sold/sold after exercising options 26,746 shares at 23.253USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Markel Group Inc: 1 director
A director at Markel Group Inc sold 1,330 shares at 2,119.120USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday...
CVB Financial Corp. Announces 145th Consecutive Quarterly Cash Dividen...
CVB Financial Corp. Announces 145th Consecutive Quarterly Cash Dividend Ontario, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- CVB Financial Corp. (NASDAQ: CVBF) (the “Company”) announced a twenty cent ($0.20) per share cash dividend with respect to the fourth quarter of 2025. This dividend was approved at the Company’s regularly scheduled Board of Directors meeting held on December 12, 2025. The quarterly dividend will be payable on or about January 13, 2026 to shareholders of record as of December 29, 2025. “Our consistent and strong financial performance has enabled the Bank to announce our 1...
- Geoffrey Von Der Ahe
- Ritika Das
- Robert Driscoll
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1...
Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host co...
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral C...
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025 Company will host conference call and live webcast to review and discuss the data at 8:00 am ET NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company’s plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursda...
Oak Valley Community Bank Welcomes Dan Greene as Vice President, Branc...
Oak Valley Community Bank Welcomes Dan Greene as Vice President, Branch Manager of Tracy Branch OAKDALE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Oak Valley Community Bank, a wholly-owned subsidiary of Oak Valley Bancorp (NASDAQ: OVLY), is pleased to welcome Dan Greene as Vice President, Branch Manager. Greene will oversee the bank’s Tracy branch at 1034 North Central Avenue, where he will guide operational strategy, nurture client relationships, and promote growth through a strong focus on service excellence. His responsibilities will also include supporting the financial needs of local...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SLGN SILGAN HOLDINGS INC.
RPD RAPID7 INC.
OPK OPKO HEALTH INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
GBCI GLACIER BANCORP INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FOXF FOX FACTORY HOLDING CORP.
EIG EMPLOYERS HOLDINGS INC.
ARCC ARES CAPITAL CORPORATION
RLMD RELMADA THERAPEUTICS
TREX TREX COMPANY INC.
VVV VALVOLINE INC.
KREF KKR REAL ESTATE FINANCE TRUST
HLNE HAMILTON LANE INCORPORATED CLASS A
SONO SONOS
VRCA VERRICA PHARMACEUTICALS
AMCR AMCOR PLC
AVTR AVANTOR
TSLX INC.
VLA SIXTH STREET SPECIALTY LENDING
MRVI INC.
FRSH ARBOR METALS
SG MARAVAI LIFESCIENCES HOLDINGS
TBBK FRESHWORKS INC.
QDEL SWEETGREEN INC
BHVN THE BANCORP
WEST INC.
SMRT QUIDEL CORP
CRVO BIOHAVEN LTD
NCDL WESTROCK COFFEE COMPANY LLC
GAM SMARTRENT INC
STRZ CERVOMED INC
GMRE NUVEEN CHURCHILL DIRECT LENDING CORP
OESX GENERAL DE ALQUILER DE MAQUINARIA
STARZ ENTERTAINMENT CORP
GLOBAL MEDICAL REIT INC.
ORION ENERGY SYSTEMS INC
Catalyst Pharmaceuticals to Participate in the Bank of America CNS The...
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Mo...
- MarketLine Department
Meritz Securities Co., Ltd. - Mergers & Acquisitions (M&A), Partnershi...
Summary Marketline's Meritz Securities Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Meritz Securities Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Allia...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.